{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:00:10Z","timestamp":1793685610058,"version":"4.5.1"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a common inflammatory skin disease characterized by eczematous lesions, dry skin and intense pruritus. Upadacitinib, a selective JAK1 inhibitor approved for moderate\u2010to\u2010severe AD in adults and adolescents, is a once\u2010daily oral treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the long\u2010term safety profile of the treatment of moderate\u2010to\u2010severe AD with upadacitinib 15\u2009mg (UPA15) or 30\u2009mg (UPA30) across 6\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Safety data for adverse events (AEs), including treatment\u2010emergent adverse events (TEAEs) and adverse events of special interest (AESIs) from three global phase 3 studies (MeasureUp 1, MeasureUp 2 and ADUp), were analysed. Data were included for all adolescent and adult patients (12\u201375\u2009years) receiving at least 1 dose of UPA15 or UPA30 across 6\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serious adverse event rates were similar for UPA15 (6.6 events [E] per 100 patient\u2010years [PY]) and UPA30 (7.4 E\/100 PY). Nasopharyngitis was the most frequently reported adverse event (UPA15, 9.8 E\/100 PY; UPA30, 9.3 E\/100 PY) excluding COVID\u201019. Event rates for serious infections were similar for both groups (UPA15, 2.2 E\/100PY; UPA30, 2.6 E\/100 PY). Rates of most AESIs were similar between UPA15 and UPA30, except for those known to be dose dependent: herpes zoster, hepatic disorder, neutropenia and CPK elevation. Adjudicated major adverse cardiovascular event incidence rates were 0.2 n\/100PY and &lt;0.1 n\/100PY for UPA15 and UPA30, respectively. Adjudicated venous thromboembolic event incidence rates were 0.1 n\/100PY for both UPA15 and UPA30. Rates of malignancy excluding non\u2010melanoma skin cancer were 0.3 n\/100PY for UPA15 and 0.5 n\/100PY for UPA30. Rates of lymphoma were &lt;0.1 n\/100PY for both groups. Rates of TEAEs leading to death were low (&lt;0.1 E\/100PYs and 0.1 E\/100 PYs for UPA15 and UPA30, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis provides information about the long\u2010term safety of upadacitinib in AD, with no new important safety signals identified for up to 6\u2009years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70172","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T11:50:07Z","timestamp":1763207407000},"page":"856-866","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6\u2009years"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher G.","family":"Bunick","sequence":"first","affiliation":[{"name":"Department of Dermatology and Program in Translational Biomedicine Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-2044","authenticated-orcid":false,"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[{"name":"Clinical Medicine Trinity College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology George Washington University School of Medicine and Health Sciences  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman\u2010Yassky","sequence":"additional","affiliation":[{"name":"Department of Dermatology and the Laboratory for Inflammatory Skin Diseases Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shahriari","sequence":"additional","affiliation":[{"name":"Department of Dermatology Yale University School of Medicine  New Haven Connecticut USA"},{"name":"Central CT Dermatology Research PLLC  Cromwell Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-8564","authenticated-orcid":false,"given":"Xinghua","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Dermatology The First Hospital of China Medical University  Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-252X","authenticated-orcid":false,"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Schleswig\u2010Holstein  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[{"name":"North Campus, Kyoto Prefectural University of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Vigna","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne M.","family":"Dilley","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"D'Andrea","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique D.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Platt","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gweneth F.","family":"Levy","sequence":"additional","affiliation":[{"name":"AbbVie, Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key276"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"e_1_2_14_7_1","volume-title":"Rinvoq (upadacitnib) extended\u2010release tablets, for oral use","author":"AbbVie Inc","year":"2025"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0029"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19391"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19232"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19581"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19862"},{"key":"e_1_2_14_13_1","unstructured":"IrvineAD SilverbergJI BunickCG VleugelsRA ChovatiyaR LimaH et\u00a0al.Efficacy and safety of upadacitinib through 188\u2009weeks in adolescents and adults with moderate\u2010to\u2010severe atopic dermatitis: phase 3 randomized clinical trial results. Revolutionizing Atopic Dermatitis; 2024; Virtual."},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad498.037"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00589-4"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.012"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14853"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20936059"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.09.023"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58081078"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.05.015"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1127104"},{"key":"e_1_2_14_25_1","doi-asserted-by":"crossref","unstructured":"VleugelsRA GradaA YueE BunickCG GalimbertiF KruegerW.Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate\u2010to\u2010severe atopic dermatitis in the United States: a population\u2010based study using claims data. Revolutionizing Alopecia Areata Vitiligo and Eczema (RAVE); 2024 June 8\u201310; Chicago IL.","DOI":"10.1093\/bjd\/ljae266.055"},{"key":"e_1_2_14_26_1","doi-asserted-by":"crossref","unstructured":"BunickCG GradaA Del RossoJ ArmstrongAW YueE KruegerW.Risk of major adverse cardiovascular events in patients with moderate\u2010to\u2010severe atopic dermatitis: a United States population\u2010based study. Revolutionizing Alopecia Areata Vitiligo and Eczema (RAVE); 2024 June 8\u201310; Chicago IL.","DOI":"10.1093\/bjd\/ljae266.057"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00538-4"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09887.x"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02490-5"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00798-0"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20674"}],"updated-by":[{"DOI":"10.1111\/jdv.70587","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000}}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70172","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70172","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:22:30Z","timestamp":1777533750000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/jdv.70172"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70172","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"2025-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}